Illumina Files Two Patent Infringement Suits in Europe for Infringement of Patents for NIPT

Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed two patent infringement suits in Europe. The patents asserted use cell-free fetal DNA for non-invasive prenatal testing (NIPT).

The first suit was filed against The Doctors Laboratory Ltd, TDL Genetics Ltd, and Ariosa Diagnostics, Inc. in the High Court of Justice, Chancery Division in the United Kingdom. The suit accuses The Doctors Laboratory and TDL Genetics’ use of the Harmony^™ NIPT test supplied by Ariosa of infringing European Patent 0 994 963.

The second suit was filed against Centrum Badan Sp z o.o. and Medgenetix Sp z o.o. in the Regional Court in Warsaw, Poland. The suit accuses Centrum and Medgenetix’s use of the Iona® NIPT test supplied by Premaitha Health PLC of infringing European Patent 2 183 693.

Illumina is seeking all available remedies, including damages and injunctive relief.

These new lawsuits follow suits previously filed against Ariosa in the United States and Premaitha in the United Kingdom.

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160107006103/en/